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Abstract. 
 
Platelet-derived growth factor-BB (PDGF-
BB) acts as a full mitogen for cultured aortic smooth 
muscle cells (SMC), promoting DNA synthesis and cell 
proliferation. In contrast, angiotensin II (Ang II) in-
duces cellular hypertrophy as a result of increased pro-
tein synthesis, but is unable to drive cells into S phase. 
In an effort to understand the molecular basis for this 
differential growth response, we have examined the 
downstream effects of PDGF-BB and Ang II on regula-
tors of the cell cycle machinery in rat aortic SMC. Both 
PDGF-BB and Ang II were found to stimulate the ac-
 
cumulation of G
 
1 
 
cyclins with similar kinetics. In addi-
tion, little difference was observed in the expression 
level of their catalytic partners, Cdk4 and Cdk2. How-
ever, while both factors increased the enzymatic activ-
ity of Cdk4, only PDGF-BB stimulated Cdk2 activity in 
late G
 
1 
 
phase. The lack of activation of Cdk2 in Ang II-
treated cells was causally related to the failure of Ang II 
to stimulate phosphorylation of the enzyme on threo-
nine and to downregulate p27
 
Kip1
 
 expression. By con-
trast, exposure to PDGF-BB resulted in a progressive 
and dramatic reduction in the level of p27
 
Kip1
 
 protein. 
The time course of p27
 
Kip1
 
 decline was correlated with a 
reduced rate of synthesis and an increased rate of deg-
radation of the protein. Importantly, the repression of 
p27
 
Kip1
 
 synthesis by PDGF-BB was associated with a 
marked attenuation of 
 
Kip1
 
 gene transcription and a 
corresponding decrease in 
 
Kip1
 
 mRNA accumulation. 
We also show that the failure of Ang II to promote S 
phase entry is not related to the autocrine production 
 
of transforming growth factor-
 
b
 
1 by aortic SMC. These 
results identify p27
 
Kip1
 
 as an important regulator of the 
phenotypic response of vascular SMC to mitogenic and 
hypertrophic stimuli.
Key words: growth factors • cell cycle • CDK inhibi-
tors • gene expression • smooth muscle cells
 
Introduction
 
The proliferation of normal mammalian cells is controlled
by an intricate network of biochemical pathways that en-
sure that each cell cycle event is performed correctly and
in proper sequence (Murray and Hunt, 1993). Growth fac-
tor-induced signals are required for progression through
the G
 
1
 
 phase and must converge, in late G
 
1
 
, on the cell cy-
cle engine to ensure the commitment of cells to enter S
phase (Pardee, 1989). The regulation of G
 
1
 
 progression
and G
 
1
 
/S transition is governed, at least in part, by the con-
certed action of cyclin-dependent kinases (Cdks)
 
1
 
 and
their regulatory cyclin subunits (Draetta, 1994; Sherr,
1994; Grana and Reddy, 1995). When quiescent cells re-
sume cycling in response to growth factors, D-type cyclins
(D1, D2, and D3) progressively accumulate during G
 
1
 
phase and assemble with their catalytic partners, Cdk4
and Cdk6. The activity of Cdk4/Cdk6 is first detected in
mid-G
 
1
 
 and increases as cells approach the G
 
1
 
/S boundary.
One major target of Cdk4/Cdk6 is the retinoblastoma pro-
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b
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tein (pRb), which upon phosphorylation dissociates from
bound transcription factors, such as E2F, enabling them to
activate genes required for DNA replication (Weinberg,
1995). Cyclin E is expressed at maximum level in late G
 
1
 
and associates with Cdk2. Biochemical and genetic data
indicate that cyclin E–Cdk2 activity is essential for entry
into S phase (van den Heuvel and Harlow, 1993; Knoblich
et al., 1994; Ohtsubo et al., 1995; Krude et al., 1997).
The activity of Cdks is regulated by a combination of
mechanisms. These include the synthesis of the cyclin and
Cdk, the assembly of these proteins into complexes, the
phosphorylation of a conserved threonine residue by Cdk-
activating kinase (CAK), and the interaction with Cdk in-
hibitory proteins (Morgan, 1995). Cdk inhibitors fall into
two genes families (Sherr and Roberts, 1995). The Ink4
family of proteins, which includes p16
 
Ink4A
 
, p15
 
Ink4B
 
,
p18
 
Ink4C
 
, and p19
 
Ink4D
 
, specifically interacts with Cdk4 and
Cdk6 to prevent cyclin D-Cdk assembly or enters into sta-
ble ternary complexes with cyclin D-Cdk, resulting in com-
plexes that are catalytically inactive (Serrano et al., 1993;
Guan et al., 1994; Hannon and Beach, 1994; Chan et al.,
1995; Hirai et al., 1995). The second family of inhibitors in-
cludes p21
 
Cip1/Waf1
 
 (El-Deiry et al., 1993; Gu et al., 1993;
Harper et al., 1993; Xiong et al., 1993; Noda et al., 1994),
p27
 
Kip1
 
 (Polyak et al., 1994a; Toyoshima and Hunter,
1994), and p57
 
Kip2
 
 (Lee et al., 1995; Matsuoka et al., 1995),
which are all structurally unrelated to the Ink4 proteins.
The Cip/kip family binds to and inhibits a broader range of
Cdks than the Ink4 family and displays a preference for
fully assembled cyclin–Cdk complexes. They inhibit the ki-
nase activity of G
 
1
 
 Cdks by stoichiometric binding to the
cyclin–Cdk complex or by physically blocking the phos-
phorylation of the Cdk subunit by CAK (Sherr and Rob-
erts, 1995). Among them, p27
 
Kip1
 
 was first identified in
transforming growth factor 
 
b
 
 (TGF-
 
b
 
)-treated cells (Pol-
yak et al., 1994b; Slingerland et al., 1994). The expression
of p27
 
Kip1
 
 is increased in serum-starved or density-arrested
cells (Firpo et al., 1994; Kato et al., 1994; Nourse et al., 1994)
and in cells exposed to antiproliferative signals like TGF-
 
b
 
,
rapamycin (Nourse et al., 1994), and cAMP (Kato et al.,
1994; L’Allemain et al., 1997). In contrast, the level of
p27
 
Kip1
 
 declines in response to mitogenic factor stimula-
tion (Kato et al., 1994; Nourse et al., 1994; Coats et al.,
1996; Winston et al., 1996; this study). Thus, in addition to
D-type cyclins, p27
 
Kip1
 
 may play an essential role in con-
necting mitogenic signaling pathways to cell cycle activa-
tion. Ectopic expression of p27
 
Kip1
 
 causes cell cycle arrest
in G
 
1
 
 phase (Polyak et al., 1994a; Toyoshima and Hunter,
1994) and, conversely, antisense inhibition of p27
 
Kip1
 
 ex-
pression suppresses quiescence in fibroblasts (Coats et al.,
1996; Rivard et al., 1996).
In cultured arterial smooth muscle cells (SMC), the pep-
tide growth factor platelet-derived growth factor (PDGF)-
BB acts as a full mitogen, promoting DNA synthesis and
cell division (Raines et al., 1990; Grainger et al., 1994).
The mitogenic action of PDGF-BB is initiated by its inter-
action with two structurally related tyrosine kinase recep-
tors that dimerize upon ligand binding, leading to activa-
tion of the intrinsic kinase domain and intermolecular
autophosphorylation (Claesson-Welsh, 1994). The phos-
phorylated tyrosine residues serve as docking sites for
multiple SH2-containing signaling molecules that include
 
Src, phosphoinositide 3-kinase (PI3-kinase), phospholi-
pase C-
 
g
 
 (PLC-
 
g
 
), SHP-2, Grb2, Shc, and Nck. Recruit-
ment and activation of these effector proteins catalyze the
formation of second messengers and propagate the signal
to downstream serine/threonine kinases, such as protein
kinase C, mitogen-activated protein (MAP) kinases, and
p70 S6 kinase, ultimately resulting in increased gene ex-
pression and DNA synthesis (Claesson-Welsh, 1994; Hel-
din, 1997).
In contrast to PDGF-BB, many investigators, including
ourselves, have shown that the peptide angiotensin II
(Ang II) induces cellular hypertrophy in cultured aortic
SMC as a result of increased protein synthesis, but is un-
able to drive cells into S phase (Geisterfer et al., 1988;
Berk et al., 1989; Chiu et al., 1991; Grainger et al., 1994;
Giasson and Meloche, 1995). On the other hand, Ang II
was reported to exert weak mitogenic effects on SMC of
resistance arteries (Dubey et al., 1992) and on aortic SMC
isolated from spontaneously hypertensive rats (Bunken-
burg et al., 1992; Itazaki et al., 1995). In vivo, a number of
studies have shown that infusion of Ang II stimulates SMC
DNA synthesis and proliferation in normal and injured rat
arteries (Daemen et al., 1991; van Kleef et al., 1992; de-
Blois et al., 1996; Su et al., 1998). However, results of in
vivo studies are difficult to interpret since the effect of
Ang II may be indirect or Ang II may simply act as a comi-
togen. It has been postulated that Ang II may be a bifunc-
tional growth factor that activates both proliferative and
antiproliferative (TGF-
 
b
 
1) signals in vascular SMC (Gib-
bons et al., 1992; Koibuchi et al., 1993). According to this
model, the autocrine production of TGF-
 
b
 
1 would deter-
mine whether vascular SMC grow by hypertrophy or hy-
perplasia in response to Ang II.
In cultured aortic SMC, the hypertrophic action of Ang
II is initiated by its interaction with the G protein-coupled
AT
 
1
 
 receptor, which stimulates the activity of PLC-
 
b
 
 to
generate the second messengers inositol 1,4,5-trisphos-
phate (InsP3) and diacylglycerol, and inhibits the activity
of adenylyl cyclase (Catt et al., 1993; Timmermans et al.,
1993). These early signaling events subsequently lead to
the activation of multiple serine/threonine kinases, which
include the MAP kinases ERK1/ERK2 (Duff et al., 1992;
Tsuda et al., 1992; Servant et al., 1996) and p70 S6 kinase
(Giasson and Meloche, 1995). Ang II also induces tyrosine
phosphorylation of multiple proteins in aortic SMC (Mol-
loy et al., 1993; Leduc et al., 1995) and stimulates the activ-
ity of cytosolic tyrosine kinases, such as p125
 
FAK
 
 (Polte et al.,
1994; Giasson et al., 1997), Pyk2 (Giasson et al., 1997), Src
(Ishida et al., 1995), and the Janus kinases Jak2 and Tyk2
(Marrero et al., 1995; Giasson et al., 1997). Despite the
fact that Ang II and PDGF-BB activate similar signal
transduction pathways, only the latter is able to induce
proliferation of aortic SMC.
In an effort to understand the molecular basis for this
differential response, we have examined the downstream
effects of PDGF-BB and Ang II on regulators of the cell
cycle machinery. We show that while both factors are able
to stimulate the activity of Cdk4, only PDGF-BB increases
the enzymatic activity of Cdk2 in late G
 
1
 
 phase. The lack
of activation of Cdk2 in Ang II-treated cells is associated
with the failure of Ang II to downregulate p27
 
Kip1
 
 expres-
sion. We also show that p27
 
Kip1
 
 abundance is regulated by 
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multiple transcriptional and posttranscriptional mecha-
nisms in vascular SMC.
 
Materials and Methods
 
Cell Culture
 
Rat aortic SMC were cultured to 80% confluence and synchronized in the
quiescent state as described previously (Giasson and Meloche, 1995). The
cells were stimulated with 100 nM Ang II (Hukabel Scientific) or 50 ng/ml
PDGF-BB (Oncogene Science) for the indicated times at 37
 
8
 
C. Mv1Lu
mink lung epithelial cells (obtained from Dr. Maureen O’Connor, Bio-
technology Research Institute of Montreal, Canada) were grown in MEM
containing 10% FBS.
 
Protein Synthesis, DNA Synthesis, and Cell
Number Measurements
 
For protein synthesis measurements, quiescent aortic SMC in 6-well plates
were stimulated with Ang II or PDGF-BB for 72 h in serum-free medium
containing 0.5 
 
m
 
Ci/ml [
 
3
 
H]leucine. For DNA synthesis measurements, qui-
escent aortic SMC in 35-mm petri dishes were stimulated for the indicated
times with Ang II or PDGF-BB and pulse-labeled with 2 
 
m
 
Ci/ml [
 
3
 
H]thy-
midine for the last 2–4 h. After the stimulation, the medium was aspirated
and the cells were incubated for a minimum of 30 min in cold 5% TCA.
The wells were then washed once with TCA and three times with tap wa-
ter. The radioactivity incorporated into TCA-precipitable material was
measured by liquid scintillation counting after solubilization in 0.1 M
NaOH. For determination of cell number, quiescent aortic SMC in 6-well
plates were stimulated with Ang II or PDGF-BB for 72 h and then were
trypsinized and counted using a hemacytometer.
 
Immunoblot Analysis
 
Cells were washed twice with ice-cold PBS and lysed in Triton X-100 lysis
buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 50 mM sodium fluoride,
5 mM EDTA, 40 mM 
 
b
 
-glycerophosphate, 1 mM sodium orthovanadate,
10
 
2
 
4
 
 M phenylmethylsulfonyl fluoride, 10
 
2
 
6
 
 M leupeptin, 10
 
2
 
6
 
 M pepstatin
A, 1% Triton X-100) for 30 min at 4
 
8
 
C. Lysates were clarified by centrifu-
gation at 13,000 
 
g
 
 for 10 min and equal amounts of lysate proteins (30–85 
 
m
 
g)
were subjected to electrophoresis on 12 or 15% acrylamide gels. Proteins
were electrophoretically transferred to Hybond-C nitrocellulose mem-
branes (Nycomed Amersham, Inc.) in 25 mM Tris, 192 mM glycine, and
fixed for 10 min in methanol/acetic acid/glycerol (40:7:3). The membranes
were blocked in TBS containing 5% nonfat dry milk and 0.1% Tween 20
for 1 h at 37
 
8
 
C before incubation for 1 h at 25
 
8
 
C with 2 
 
m
 
g/ml of mAb to
cyclin D1 (DCS-6), cyclin D2 (DCS-3.1), or cyclin D3 (DCS-22; NeoMark-
ers), or 1 
 
m
 
g/ml of polyclonal antibody to cyclin E (SC-481), Cdk2 (SC-
163), Cdk4 (SC-260), or p27
 
Kip1
 
 (SC-528; Santa Cruz Biotechnology) in
blocking solution. After washing four times in TBS, 0.1% Tween 20, the
membranes were incubated for 1 h with HRP-conjugated goat anti–rabbit
or anti–mouse IgG (1:10,000) in blocking solution. Immunoreactive
bands were visualized by enhanced chemiluminescence (Nycomed Amer-
sham, Inc.).
For coprecipitation studies, total lysate proteins (200–500 
 
m
 
g) were in-
cubated for 3 h at 4
 
8
 
C with anticyclin E antibody and the immune com-
plexes were collected with protein A–Sepharose beads (Pharmacia Bio-
tech). The beads were washed five times with Triton X-100 lysis buffer,
resuspended in denaturing sample buffer, and the eluted proteins were
analyzed by immunobloting.
 
Protein Kinase Assays
 
The phosphotransferase activity of Cdk2 was measured by immune com-
plex kinase assay using histone H1 as substrate as described previously
(Meloche, 1995). In brief, lysate proteins (200 
 
m
 
g) were subjected to im-
munoprecipitation with 1 
 
m
 
g of anti-Cdk2 antibody preadsorbed to pro-
tein A–Sepharose beads for 2 h at 4
 
8
 
C. The immune complexes were
washed three times with Triton X-100 lysis buffer and once with kinase as-
say buffer (20 mM Hepes, pH 7.4, 5 mM MgCl
 
2
 
, 1 mM dithiothreitol). His-
tone H1 kinase activity was assayed by resuspending the beads in a total
volume of 40 
 
m
 
l of kinase assay buffer containing 0.25 mg/ml histone H1
(Boehringer Mannheim Corp.), 100 
 
m
 
M ATP, and 10 
 
m
 
Ci [
 
g
 
-
 
32
 
P]ATP.
The reactions were initiated by the addition of ATP, incubated at 30
 
8
 
C for
 
5 min, and stopped by addition of 2
 
3
 
 denaturing sample buffer. The sam-
ples were analyzed by SDS-gel electrophoresis and the bands correspond-
ing to histone H1 were excised and counted.
For inhibition experiments, extracts of PDGF-BB–stimulated cells con-
taining active Cdk2 were mixed with boiled (5 min at 100
 
8
 
C) extracts of
Ang II-stimulated cells (1:1 ratio; 200 
 
m
 
g protein of each lysate) for 1.5 h
at 4
 
8
 
C before immunoprecipitation of Cdk2 and kinase assay. Immunode-
pletion of p27
 
Kip1
 
 was performed by incubating 200 
 
m
 
g of Ang II-treated
cell extract with 5 
 
m
 
g of anti-p27
 
Kip1
 
 antibody for 2 h at 4
 
8
 
C. The resulting
supernatant was then used for the inhibition experiment. Specificity of
p27
 
Kip1
 
 immunodepletion was assessed by preincubating the anti-p27
 
Kip1
 
antibody with excess immunogenic peptide (50 
 
m
 
g of SC-528P; Santa-Cruz
Biotechnology) for 2 h at 4
 
8
 
C before incubation with Ang II-treated cell
extract.
Cdk4 enzymatic assays were performed as described (Matsushime et
al., 1994) with some modifications. After stimulation, the cells were
washed twice with ice-cold PBS and lysed in Tween 20 lysis buffer (50
mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 10 mM EGTA, 20
mM 
 
b
 
-glycerophosphate, 50 mM sodium fluoride, 0.1 mM sodium ortho-
vanadate, 10
 
2
 
4
 
 M phenylmethylsulfonyl fluoride, 10
 
2
 
6
 
 M leupeptin, 10
 
2
 
6
 
 M
pepstatin A, and 0.1% Tween 20). The cells were scraped from the
plates and sonicated at 4
 
8
 
C (once for 10 s). Cellular lysates were clarified
by centrifugation and 150 
 
m
 
g of lysate proteins were precleared for 1 h
with 5 
 
m
 
l of normal rabbit serum and then incubated for 3 h at 4
 
8
 
C with 1
 
m
 
g of anti-Cdk4 antibody preadsorbed to protein A–Sepharose beads.
The immune complexes were washed twice with Tween 20 lysis buffer
and twice with kinase assay buffer (50 mM Hepes, pH 7.4, 10 mM MgCl
 
2
 
,
2.5 mM EGTA, 1 mM dithiothreitol, 10 mM 
 
b
 
-glycerophosphate, 1 mM
sodium fluoride, and 0.1 mM sodium orthovanadate). pRb kinase activity
was assayed by resuspending the beads in a total volume of 40 
 
m
 
l of ki-
nase assay buffer containing 1 
 
m
 
g glutathione S-transferase (GST)-pRb
protein (amino acids 792–928), 0.2 mg/ml BSA, 20 
 
m
 
M ATP, and 10 
 
m
 
Ci
[
 
g
 
-
 
32
 
P]ATP. The reactions were incubated at 30
 
8
 
C for 30 min and stopped
by addition of 2
 
3
 
 denaturing sample buffer. The samples were resolved
by SDS-gel electrophoresis and the radioactivity incorporated into GST-
pRb was counted.
The enzymatic activity of CAK was measured essentially as described
(Musgrove et al., 1998). Cellular extracts (400 
 
m
 
g protein) prepared in
CAK lysis buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM EDTA,
2.5 mM EGTA, 1 mM dithiothreitol, 10% glycerol, 10 mM 
 
b
 
-glycero-
phosphate, 1 mM sodium fluoride, 0.1 mM sodium orthovanadate, 10
 
2
 
4
 
 M
phenylmethylsulfonyl fluoride, 10
 
2
 
6
 
 M leupeptin, 10
 
2
 
6
 
 M pepstatin A,
and 0.1% Tween 20) were precleared as described above and then incu-
bated for 3.5 h at 4
 
8
 
C with 5 
 
m
 
g of anti-Cdk7 antibody (06-377; Upstate
Biotechnology) preadsorbed to protein A–Sepharose beads. The im-
mune complexes were washed twice with lysis buffer and twice with ki-
nase assay buffer (50 mM Hepes, pH 7.5, 30 mM MgCl
 
2
 
, and 1 mM
dithiothreitol). CAK activity was assayed by resuspending the beads in
40 
 
m
 
l of kinase assay buffer containing 5 
 
m
 
g of GST-Cdk2K33M, 90 
 
m
 
M
ATP, and 10 
 
m
 
Ci [
 
g
 
-
 
32
 
P]ATP. The reactions were incubated for 20 min at
30
 
8
 
C and stopped by addition of 2
 
3
 
 denaturing sample buffer. The sam-
ples were analyzed by SDS-gel electrophoresis and the bands corre-
sponding to GST-Cdk2K33M were excised and counted. No CAK kinase
activity was detected in samples subjected to immunoprecipitation with
beads alone.
The recombinant GST fusion proteins of pRb and Cdk2K33M were ex-
pressed in Escherichia coli by transformation with plasmids pGEX-Rb and
pGEX-Cdk2K33M (obtained from Drs. Jacques Pouysségur, Centre de Bio-
chimie-CNRS, Nice, France, and Tomi P. Mäkelä, University of Helsinki, Hel-
sinki, Finland, respectively) and purified as described (Matsushime et al., 1994).
Phosphorous 32 Labeling and Immunoprecipitation
Quiescent aortic SMC in 100-mm petri dishes were stimulated for 10 or 20 h
with Ang II or PDGF-BB and labeled for the last 5 h in bicarbonate- and
phosphate-free Hepes-buffered MEM containing 0.5 mCi/ml [32P]phos-
phoric acid. The cells were then washed twice with ice-cold PBS and lysed
in Triton X-100 lysis buffer. After clarification, the lysates were pre-
cleared for 1 h with 5 ml of normal rabbit serum and Cdk2 was immuno-
precipitated as described above. Immune complexes were washed five
times with Triton X-100 lysis buffer. Proteins were eluted by heating at
958C for 5 min in denaturing sample buffer and analyzed by SDS-gel elec-
trophoresis on 10% acrylamide gels. The proteins were then electro-
phoretically transferred to PVDF membranes (Millipore) in 25 mM Tris,
192 mM glycine, and 20% methanol, and visualized by autoradiography.The Journal of Cell Biology, Volume 148, 2000 546
Phosphoamino Acid Analysis
The labeled band corresponding to Cdk2 was excised from the PVDF
membrane and subjected to partial acid hydrolysis in 5.7 M HCl for 1 h at
1108C (Kamps, 1991). The resulting phosphoamino acids, along with unla-
beled phosphoamino acid standards (0.2 mg/ml), were separated by one-
dimensional thin layer electrophoresis using an optimized pH 2.5 buffer
(Jelinek and Weber, 1993). The standards were visualized by ninhydrin
staining and the labeled amino acids by autoradiography.
Biosynthetic Labeling Experiments
To examine the turnover of p27Kip1 protein, quiescent aortic SMC in
100-mm petri dishes were pulse-labeled for 1 h with 166 mci/ml of [35S]me-
thionine and [35S]cysteine and then chased for the indicated times in se-
rum-free medium containing excess methionine and cysteine and either
Ang II or PDGF-BB. The cells were then washed twice with ice-cold PBS
and lysed in Triton X-100 lysis buffer. Lysates (500 mg proteins) were pre-
cleared for 1 h with 5 ml of normal rabbit serum and the resulting superna-
tants were incubated with protein A–Sepharose beads preadsorbed with
2 mg of anti-p27Kip1 for 4 h at 48C. Immune complexes were washed five
times with Triton X-100 lysis buffer. Proteins were eluted by heating at
958C for 5 min in denaturing sample buffer and analyzed by SDS-gel elec-
trophoresis on 12% acrylamide gels. The p27Kip1 protein was detected by
fluorography and quantified using a PhosphorImager apparatus.
For labeling newly synthesized proteins, cells were stimulated for the
indicated times, rinsed with methionine- and cysteine-free medium, and
incubated with 250 mCi/ml of [35S]methionine and [35S]cysteine. Labeling
was allowed to proceed for the last 20 min. Cell lysis and immunoprecipi-
tation of p27Kip1 were conducted as described above.
Northern Blot Analysis
Total RNA was extracted by a modified version of the guanidinium thio-
cyanate procedure as described (Chomczynski and Sacchi, 1987; Chom-
czynski, 1993). Equal amounts of total RNA (15–25 mg) were denaturated
and resolved by electrophoresis in a 1% agarose gel containing 1.8%
formaldehyde. The RNA was transferred to Hybond-N membranes
(Nycomed Amersham, Inc.), fixed, and hybridized with 32P-labeled
probes. Hybridization was carried out in hybridization medium (53 SSC
[13 SSC 5 150 mM NaCl, 15 mM sodium citrate], 0.1% SDS, 53 Den-
hardt’s solution [13 Denhardt’s 5 0.02% Ficoll 400, 0.02% polyvinyl pyr-
rolidone, and 0.02% BSA], 50% formamide, and 100 mg/ml herring sperm
DNA) containing the labeled probe (1–2 3 106 cpm/ml) for 16 h at 428C.
The membranes were washed twice at 258C for 15 min in 23 SSC, 0.1%
SDS, and twice at 608C for 30 min in 0.53 SSC, 0.1% SDS. The extent of
hybridization was analyzed with a PhosphorImager apparatus. The results
were normalized to 18S ribosomal RNA.
The probes used were: 1.5-kb EcoRI fragment of human p27Kip1 cDNA
(provided by Dr. Joan Massagué, Memorial Sloan-Kettering Cancer Cen-
ter, NY) and a DNA oligonucleotide derived from the rat 18S ribosomal
RNA sequence.
Nuclear Run-On Transcription Assays
Nuclei were prepared as described by Greenberg and Bender (1997). Vas-
cular SMC were washed twice with ice-cold PBS and scraped from plates
in PBS, 1 mM EDTA. Cell pellets were collected by centrifugation and re-
suspended in cold lysis buffer (10 mM Tris-HCl, pH 7.4, 3 mM CaCl2, 2 mM
MgCl2, 1% NP-40). The cells were then disrupted in a Dounce homoge-
nizer and the nuclei were sedimented at 500 g for 5 min. The nuclei were
resuspended in 50 mM Tris-HCl, pH 8.3, 5 mM MgCl2, 0.1 mM EDTA,
and 40% glycerol and frozen in liquid nitrogen. For run-on transcription
reactions, thawed nuclei (8 3 107) were resuspended in 400 ml of reaction
buffer containing 5 mM Tris-HCl, pH 8.0, 2.5 mM MgCl2, 150 mM KCl,
5 mM dithiothreitol, 20 U/ml RNA guard (Pharmacia Biotech), 1 mM
each of ATP, GTP, and CTP, and 600 mCi of a[32P]UTP (Nycomed Amer-
sham, Inc.: 800 Ci/mmol) and incubated at 378C for 30 min. Transcription
was stopped by the addition of 40 mg DNase I in 1 ml of HSB buffer and
incubated for 5 min at 308C. Then, 10 ml of 20 mg/ml proteinase K in 0.5 M
Tris-HCl, pH 7.4, 125 mM EDTA, and 5% SDS was added to the reac-
tion mixture, followed by incubation for 30 min at 428C. The 32P-labeled
RNA was extracted with phenol/chloroform and unincorporated nucle-
otides were removed by chromatography through a Sephadex G-50
(Pharmacia Biotech) column. Each plasmid DNA gene insert was dena-
turated and immobilized to nitrocellulose membranes using a dot-blot
apparatus. The membranes were hybridized with 32P-labeled RNA in
53 SSC, 53 Denhardt’s, 50% formamide, 4 mM EDTA, 0.5 mg/ml
salmon sperm DNA, and 0.25 mg/ml yeast tRNA at 558C for 24 h. The
membranes were washed extensively at 608C in 0.53 SSC, 0.1% SDS.
The extent of hybridization was analyzed with a PhosphorImager appa-
ratus.
[3H]Uridine Pulse-Chase Experiments
Quiescent aortic SMC were pretreated for 2 h with 20 mM glucosamine
(Sigma Chemical Co.) to deplete the UTP pool, washed, and pulse-
labeled with 100 mCi/ml [3H]uridine (26 Ci/mmol; Nycomed Amersham,
Inc.) for 12 h. The unincorporated [3H]uridine-containing medium was
removed and the cells were incubated for an additional 2 h in serum-free
medium containing 20 mM glucosamine, 5 mM uridine, and 5 mM cyti-
dine. The chase was then continued for 4 h in the same medium contain-
ing Ang II or PDGF-BB. At various intervals, the cells were washed with
PBS and total RNA was isolated as described above. Equivalent amounts
of 3H-labeled RNA were hybridized to 5 mg of linearized plasmid DNA
immobilized onto a nitrocellulose membrane. Hybridization was per-
formed at 458C for 4 d, as described in the previous section. The mem-
branes were washed extensively at 558C in 0.53 SSC, 0.1% SDS. After
drying, the radioactivity of each spot was determined by liquid scintilla-
tion counting.
TGF-b1 Bioassay
TGF-b1 bioassay was conducted essentially as described previously (Gib-
bons et al., 1992). Recombinant TGF-b1 and TGF-b1 neutralizing anti-
body (TNA) was a generous gift from Dr. Maureen O’Connor. In brief,
Mv1Lu cells were plated at a density of 5 3 105 cells per well in 24-well
plates. After 6 h of serum exposure, the cells were washed with serum-
free medium, then incubated with conditioned medium or TGF-b1 in se-
rum-free medium for 24 h. The rate of DNA synthesis was measured by
pulse-labeling cells with 2 mCi/ml [3H]thymidine during the last 6 h of in-
cubation. For each experiment, a standard curve was constructed with in-
creasing concentrations of recombinant TGF-b1. Ang II conditioned me-
dium was obtained from aortic SMC stimulated for 24 h with Ang II and
was added to Mv1Lu cells at two dilutions (1:5 and 1:10).
TNA was purified by protein A–agarose chromatography. The anti-
body was used at a concentration of 10–15 mg/ml, which completely blocks
the growth inhibitory effect of TGF-b1 in Mv1Lu cells.
Results
PDGF-BB, but Not Ang II, Induces DNA Synthesis in 
Aortic SMC
We compared the ability of the vascular growth factors
PDGF-BB and Ang II to stimulate the rate of DNA syn-
thesis in quiescent rat aortic SMC. As previously reported
(Geisterfer et al., 1988; Berk et al., 1989; Chiu et al., 1991;
Giasson and Meloche, 1995), treatment of aortic SMC
with Ang II had no significant effect on DNA synthesis, as
measured by [3H]thymidine incorporation (Fig. 1 A). In
contrast, addition of PDGF-BB strongly increased the rate
of DNA synthesis, which reached a peak (180-fold over
basal level) at 24 h after stimulation. PDGF-BB also in-
duced cellular division as reflected by an increase in SMC
number and by the small ratio between [3H]leucine incor-
poration and cell number (Fig. 1 B). Ang II did not pro-
mote cell division, but caused cellular hypertrophy by in-
creasing the rate of protein synthesis per cell over a period
of 72 h (Fig. 1 B). This finding suggests that cell cycle
progression is not delayed in Ang II-stimulated cells,
but rather, that cells are arrested in G1 phase. Thus,
PDGF-BB is a strong mitogenic factor for rat aortic SMC,
promoting DNA synthesis and cellular division, whereas
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Ang II Fails to Stimulate the Activity of Cdk2 in
Aortic SMC
In an effort to understand the molecular basis for this dif-
ferential response of aortic SMC to vascular growth fac-
tors, we examined the downstream effects of PDGF-BB
and Ang II on regulators of the cell cycle machinery. We
first analyzed the regulated expression of G1 cyclins. Fig. 2
A shows that both PDGF-BB and Ang II stimulated the
accumulation of D-type cyclins with similar kinetics. The
expression of cyclin D1, D2, and D3 started to increase at
4 h poststimulation and reached a maximal level by 12–16 h.
Cyclin E expression was already detectable in quiescent
cells. Treatment with PDGF-BB caused a small but signifi-
cant increase in cyclin E expression, which was delayed
compared with D-type cyclins (Fig. 2 A). Ang II had little
effect on cyclin E expression. It should also be noted that
PDGF-BB promoted higher levels of cyclin D1 accumula-
tion than Ang II in aortic SMC. This is in agreement with
previous observations showing that the extent of cyclin D1
accumulation is correlated with the mitogenic potential of
growth factors and their ability to induce sustained ERK1/
ERK2 activation (Lavoie et al., 1996; and data not shown).
Little difference was observed in the expression level of
the catalytic subunits Cdk4 and Cdk2, which were present
in all extracts, including those prepared from quiescent
cells (Fig. 2 B). However, we noted that treatment with
PDGF-BB results in the late appearance of a faster mi-
grating species of Cdk2, which is indicative of phosphory-
lation of the enzyme on threonine 160 (Gu et al., 1992).
Only the slower migrating form of Cdk2 was observed in
Ang II-stimulated cells.
Figure 1. Comparative effects of Ang II and PDGF-BB on the
growth of aortic SMC. A, DNA synthesis. Quiescent rat aortic
SMC were stimulated for different periods of time with 100 nM
Ang II (s) or 50 ng/ml PDGF-BB (d) and the rate of DNA syn-
thesis was measured by [3H]thymidine incorporation. Each value
represents the mean 6 SEM of triplicate determinations. B, Cell
protein content. Quiescent aortic SMC were stimulated with Ang
II or PDGF-BB for 72 h. The rate of protein synthesis was mea-
sured by [3H]leucine incorporation and the number of cells
counted on parallel plates. The results are expressed as the rela-
tive ratio between [3H]leucine incorporation and cell number.
Each value represents the mean 6 SEM of triplicate determina-
tions. Cell numbers for this experiment were: control (cont),
374,167  6  53,428 cells; Ang II, 312,000 6 28,369 cells; PDGF-BB,
917,500 6 42,120 cells. The data are representative of at least
three different experiments with similar results.
Figure 2. Effects of Ang II and PDGF-BB on the accumulation
of G1 cyclins and the expression level of Cdks in aortic SMC.
Quiescent aortic SMC were stimulated with 100 nM Ang II or 50
ng/ml PDGF-BB for different times over a 24-h period. Equal
amounts of lysate proteins were resolved by SDS-gel electro-
phoresis on 12% acrylamide gels and transferred to nitrocellu-
lose membranes. The membranes were probed with antibodies
specific to the different cyclins and Cdks. The proteins were visu-
alized by chemiluminescence detection. Similar results were ob-
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We next measured the enzymatic activity of CAK,
Cdk4, and Cdk2 after treatment of aortic SMC with the
two vascular growth factors. CAK, Cdk4, and Cdk2 were
selectively immunoprecipitated from cell lysates and their
activity assayed in vitro using GST-Cdk2, GST-pRb, and
histone H1 as substrates, respectively. As observed in
other cellular models (Sclafani, 1996), CAK enzymatic ac-
tivity was the same in quiescent and growth factor-treated
aortic SMC (Fig. 3 A). Both Ang II and PDGF-BB in-
creased the Rb kinase activity of Cdk4, which became de-
tectable at eight hours and remained elevated up to the
end of G1 phase (Fig. 3 B). Notably, Ang II treatment of
aortic SMC induced a delayed Rb kinase activity as com-
pared with PDGF-BB treatment. These results most likely
reflect the quantitative differences in the ability of Ang II
and PDGF-BB to regulate the expression of cyclin D1
(Fig. 2 A). Both factors equally stimulated Cdk4 activity
after 16 h of exposure. As expected, stimulation of aortic
SMC with the mitogenic factor PDGF-BB strongly in-
creased Cdk2-associated histone H1 kinase activity, which
was first detected at 12 h and reached a maximum in S
phase (Fig. 3 C). In contrast, treatment with Ang II failed
to induce any detectable Cdk2 activity over the same pe-
riod of time. Thus, we carried out a series of experiments
to explain the inability of Ang II to activate Cdk2. Since
CAK-mediated phosphorylation of threonine 160 on Cdk2
is required for kinase activation (Morgan, 1995), we first
analyzed the phosphorylation state of Cdk2 after immuno-
precipitation from 32P-labeled cells stimulated with Ang II
or PDGF-BB. Fig. 4 A shows that the lack of activation of
Cdk2 in Ang II-treated cells was associated with the fail-
ure of Ang II to stimulate phosphorylation of the enzyme
on threonine. On the other hand, addition of PDGF-BB
resulted in the phosphorylation of Cdk2 on threonine, ty-
rosine, and serine residues after 20 h (Fig. 4 B). Indeed, it
has been reported in HeLa cells that most of the phosphor-
ylation of Cdk2 on tyrosine (tyrosine 15) occurs on Cdk2
molecules that are also phosphorylated on threonine 160
(Gu et al., 1992). The absence of CAK-mediated threo-
nine phosphorylation of Cdk2 in Ang II-treated cells was
not attributable to the inability of Cdk2 to form complexes
with cyclin E. Immunoblot analysis showed that cyclin E
immunoprecipitates from quiescent aortic SMC already
contained a significant amount of Cdk2 and that treatment
with PDGF-BB caused a further increase in complex for-
mation that became apparent only after 16 h of stimula-
tion (Fig. 4 C). In addition, detailed kinetic analysis of
Cdk2 phosphorylation and activity revealed that 10–12 h
of PDGF-BB stimulation (thus before induction of cyclin
E expression and increased cyclin E–Cdk2 complex for-
mation) is sufficient to promote Cdk2 phosphorylation on
threonine (Fig. 4 A; and data not shown) and to activate
the enzyme (Fig. 3 C). These results indicate that mecha-
nisms other than increased cyclin E expression or cyclin
E–Cdk2 complex assembly account for the inability of
Ang II to induce threonine 160 phosphorylation of Cdk2
and to stimulate the activity of the enzyme in aortic SMC.
Differential Modulation of p27Kip1 Expression by 
PDGF-BB and Ang II
In addition to its ability to disrupt the catalytic activity of
phosphorylated cyclin-bound Cdks (Russo et al., 1996),
the inhibitor p27Kip1 can also sterically interfere with the
phosphorylation of Cdks by CAK (Kato et al., 1994;
Polyak et al., 1994a; Aprelikova et al., 1995). To determine
whether p27Kip1 was a determinant factor in the differen-
tial regulation of Cdk2 activation by mitogenic and hyper-
trophic factors, we compared the levels of p27Kip1 protein
expression. The expression of p27Kip1 protein was elevated
in quiescent aortic SMC and decreased progressively upon
Figure 3. Regulation of CAK, Cdk4, and Cdk2 enzymatic activ-
ity by Ang II and PDGF-BB during G1 progression. Quiescent
aortic SMC were stimulated for different times with 100 nM Ang
II (h) or 50 ng/ml PDGF-BB (j). Detergent lysates of the cells
were prepared and equal amounts of proteins were subjected to
immunoprecipitation with specific anti-Cdk7 (A), anti-Cdk4 (B),
or anti-Cdk2 (C) antibodies. The phosphotransferase activity of
the immunoprecipitates was assayed as described in Materials
and Methods using GST-Cdk2K33M, GST-pRb, and histone H1
as substrates, respectively. The enzymatic activities are expressed
as picomoles of phosphate incorporated into the substrate per
min per mg of lysate protein. Similar results were obtained in
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treatment of cells with the mitogenic factor PDGF-BB
(Fig. 5 A). The decrease in p27Kip1 level was already evi-
dent four hours after PDGF-BB exposure. After 20 h of
stimulation with PDGF-BB, the expression of p27Kip1 was
reduced by z80%. In contrast, Ang II had a negligible ef-
fect on the expression of the Cdk inhibitory protein. Im-
portantly, we found that mixing of boiled extract from
Ang II-stimulated cells with an equal amount of extract
from cells treated for 20 h with PDGF-BB significantly re-
duced Cdk2-associated histone H1 kinase activity (Fig. 5
B). p27Kip1 previously has been shown to be heat-stable
(Polyak et al., 1994b), thus making it a good candidate for
the inhibitory factor of Ang II-boiled extracts. Indeed, the
Cdk2 inhibitory activity present in Ang II-treated cells was
completely eliminated after immunodepletion of p27Kip1
with a specific antibody (Fig. 5 B). Preincubation of the
anti-p27Kip1 antibody with a saturating amount of immuno-
genic peptide completely restored the Cdk2 inhibitory ac-
tivity, confirming that p27Kip1 is the major factor responsi-
Figure 4. Ang II fails to stimulate the phosphorylation of Cdk2.
A, Phosphorylation of Cdk2. Quiescent aortic SMC were stimu-
lated for 20 h with 100 nM Ang II or for 10 and 20 h with 50 ng/ml
PDGF-BB and labeled with [32P]phosphoric acid during the last 5 h.
Cell lysates were prepared and Cdk2 was immunoprecipitated
using a specific antibody preadsorbed to protein A–Sepharose
beads. The immunoprecipitated proteins were resolved by SDS-
gel electrophoresis on 10% acrylamide gel, transferred to PVDF
membrane, and analyzed by autoradiography. B, Phosphoamino
acid analysis. The 32P-labeled protein band corresponding to
Cdk2 was excised from the PVDF membrane and subjected to
partial acid hydrolysis. The phosphorylated amino acids were
separated by one-dimensional thin layer electrophoresis. The po-
sitions of phosphoserine (S), phosphothreonine (T), and phos-
photyrosine (Y) are indicated. C, Complex formation between
Cdk2 and cyclin E. Quiescent aortic SMC were stimulated with
100 nM Ang II or 50 ng/ml PDGF-BB for different times over a
24-h period. Cell lysates were prepared and subjected to immu-
noprecipitation with cyclin E-specific antibody. The immunopre-
cipitated proteins were then analyzed by immunobloting with
anti-Cdk2 antibody. Similar results were obtained in three differ-
ent experiments.
Figure 5. Differential modulation of p27Kip1 expression by Ang II
and PDGF-BB. A, Expression of p27Kip1 protein. Quiescent aor-
tic SMC were stimulated with 100 nM Ang II or 50 ng/ml PDGF-
BB for different times over a 24-h period. Equal amounts of ly-
sate proteins were resolved by SDS-gel electrophoresis on 12%
acrylamide gel and transferred to nitrocellulose membrane. The
membrane was probed with anti-p27Kip1 antibody and the pro-
teins visualized by chemiluminescence detection. B, Inhibitory
activity of Ang II extracts. Quiescent aortic SMC were stimulated
for 20 h with 100 nM Ang II or 50 ng/ml PDGF-BB. Extracts
from PDGF-BB-treated cells, which contain active Cdk2, were
prepared and mixed with boiled extracts from Ang II-stimulated
cells as described in Materials and Methods. After incubation for
90 min at 48C, Cdk2 was immunoprecipitated and histone H1 ki-
nase activity was determined. p27Kip1 was immunodepleted from
boiled extracts by incubation for 1 h at 48C with anti-p27Kip1 anti-
body. Specificity of p27Kip1 immunodepletion was confirmed by
preincubation of the antibody with excess immunogenic (block-
ing) peptide. The enzymatic activities are expressed as picomoles
of phosphate incorporated into histone H1 per min per mg of ly-
sate protein. C, Decreased association of p27Kip1 with cyclin
E–Cdk2 complexes in PDGF-BB–treated cells. Detergent lysates
of aortic SMC stimulated for the indicated times with 100 nM
Ang II or 50 ng/ml PDGF-BB were subjected to immunoprecipi-
tation with anticyclin E antibody and analyzed by immunobloting
with antibody to p27Kip1. Similar results were obtained in three
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ble for this activity. Addition of boiled extracts from
PDGF-BB–stimulated cells, which contain very low levels
of p27Kip1 (Fig. 5 A), did not inhibit Cdk2 activity of ex-
tracts from cells exposed to PDGF-BB for 20 h (data not
shown).
The inability of Ang II to downregulate expression of
p27Kip1 in aortic SMC was also reflected by the strong and
sustained association of the inhibitor with cyclin E–Cdk2
complexes. When cells exposed to Ang II or PDGF-BB
were subjected to immunoprecipitation with anticyclin E
antibody, the level of associated p27Kip1 was found to be
significantly lowered after 16 h of PDGF-BB treatment
compared with Ang II-stimulated cells (Fig. 5 C). From
these results, we conclude that the failure of Ang II to
downregulate p27Kip1 expression is responsible, at least in
part, for the inability of Ang II to induce Cdk2 activation,
DNA synthesis, and cellular division in aortic SMC.
The Abundance of p27Kip1 Is Regulated both at the Level 
of mRNA Expression and Protein Stability in
Aortic SMC
We next addressed the question of how the levels of
p27Kip1 are regulated by vascular growth factors. Studies in
other cell systems have shown that the abundance of
p27Kip1 is controlled by multiple posttranscriptional pro-
cesses including degradation through the ubiquitin–pro-
teasome pathway (Pagano et al., 1995) and changes in
translation rates (Agrawal et al., 1996; Hengst and Reed,
1996; Millard et al., 1997). To determine the rate of p27Kip1
turnover, pulse-chase experiments were conducted on aor-
tic SMC treated with Ang II or PDGF-BB. The rate of
degradation of p27Kip1 was clearly increased in cells ex-
posed to PDGF-BB (Fig. 6, A and B). Quantitation of the
data revealed that the half-life of the protein was reduced
to six hours, compared with that of arrested (8.9 h) or Ang
II-treated cells (8.2 h).
The rate of synthesis of p27Kip1 was also affected by treat-
ment with vascular growth factors. As shown in Fig. 6 C,
the synthesis of p27Kip1 was dramatically repressed after
two hours of PDGF-BB stimulation and this inhibition per-
sisted for up to 20 h. Ang II treatment also resulted in the
repression of p27Kip1 synthesis, but the effect was less
marked and more transient, the rate of synthesis returning
to basal level within 6–12 h of stimulation. To verify
whether the decline in p27Kip1 synthesis was associated with
a decrease in Kip1 mRNA accumulation, we measured the
steady-state levels of Kip1 mRNA by Northern hybridiza-
tion. Results of these experiments clearly demonstrated
that expression of Kip1 mRNA is regulated in aortic SMC.
PDGF-BB treatment resulted in a rapid and marked de-
crease of Kip1 mRNA, which was almost undetectable by
two hours of stimulation, and then slowly returned to its
quiescent level at z12 h (Fig. 7). Ang II also reduced ex-
pression of Kip1 mRNA, but the effect was smaller in com-
parison to PDGF-BB. The time course of Kip1 mRNA
downregulation and reappearance correlated well with the
transient decrease in the rate of p27Kip1 synthesis seen after
PDGF-BB and Ang II treatment (Fig. 6 C). This suggests
that repression of p27Kip1 synthesis by vascular growth fac-
tors is likely attributable, at least in part, to a correspond-
ing decrease of Kip1 mRNA abundance.
There was a tight temporal relationship between the de-
crease in the rate of p27Kip1 synthesis observed at two
hours after stimulation, the increased rate of degradation
of the protein, and the change in the total amount of
p27Kip1. If we consider that the rate of p27Kip1 synthesis is
almost null after two to three hours of PDGF-BB treat-
ment and that the half-life of the protein is approximately
six hours (Fig. 6), the level of p27kip1 protein should be re-
duced by z50% eight to nine hours after mitogenic stimu-
lation. This estimation is consistent with the data pre-
sented in Fig. 5 A.
Figure 6. Downregulation of p27Kip1 expression is associated with
increased turnover of the protein and repression of its synthesis.
A, Turnover of p27Kip1 protein. Quiescent aortic SMC were
pulse-labeled with [35S]methionine/[35S]cysteine for 60 min, after
which the medium was changed with fresh medium alone or con-
taining 100 nM Ang II or 50 ng/ml PDGF-BB. At different times,
cell extracts were prepared and subjected to immunoprecipita-
tion with anti-p27Kip1 antibody. After extensive washing, the im-
munoprecipitated proteins were separated by electrophoresis on
12% acrylamide gel and analyzed by fluorography using a Phos-
phorImager. B, Densitometric analysis of the data shown in A.
s, Unstimulated cells (r 5 0.958); d, Ang II-treated cells (r 5
0.969); m, PDGF-BB–treated cells (r 5 0.950). The data points
represent mean 6 SEM of four separate experiments. C, Synthe-
sis of p27Kip1. Quiescent aortic SMC were stimulated with Ang II
or PDGF-BB for the times indicated and metabolically labeled
with [35S]methionine/[35S]cysteine during the last 20 min of incu-
bation. Preparation of cell extracts and immunoprecipitation
were conducted as above. Similar results were obtained in four
separate experiments.Servant et al. Regulation of p27Kip1 Expression in Vascular SMC 551
PDGF-BB Reduces the Rate of Kip1 Gene 
Transcription in Aortic SMC
To determine whether PDGF-BB–mediated downregula-
tion of Kip1 mRNA involves a transcriptional mechanism,
nuclear run-on transcription assays were performed on nu-
clei isolated from quiescent and growth factor-treated aor-
tic SMC. Fig. 8 shows that PDGF-BB markedly decreased
the rate of Kip 1 transcription (z90% reduction of control
value) after two hours of stimulation. Addition of Ang II
also caused a significant attenuation of Kip1 transcription,
but the effect was less pronounced than that of PDGF-BB.
As a control, we also examined transcription of the gene
encoding smooth muscle a-actin, which is known to be in-
duced by Ang II, but not PDGF-BB, in vascular SMC
(Corjay et al., 1990; Hautmann et al., 1997). In agreement
with these studies, only Ang II enhanced smooth muscle
a-actin transcription. No appreciable difference in the
transcription of GAPDH gene was observed in response
to Ang II or PDGF-BB treatment.
We next examined the effect of PDGF-BB and Ang II
on the stability of Kip1 mRNA using two independent ap-
proaches: mRNA decay in the presence of the transcrip-
tional inhibitor 5,6-Dichloro-1-b-D-ribofuranosylbenzimi-
diazole (DRB) and pulse-chase analysis with [3H]uridine.
With the use of DRB, the half-life of Kip1 mRNA was es-
timated to be 4.7 h in unstimulated cells (Fig. 9 A). Treat-
ment with PDGF-BB or Ang II accelerated the degrada-
tion of Kip1 mRNA, decreasing the half-life to 2.2 h and
2.3 h, respectively. Comparable results were obtained with
the pulse-chase method with a calculated half-life of 3.6 h
in quiescent cells, and of 1.9 h and 2.0 h in cells stimulated
with PDGF-BB and Ang II, respectively (Fig. 9 B). These
findings indicate that both PDGF-BB and Ang II destabi-
lize Kip1 mRNA to the same extent in aortic SMC. We
found that the calculated half-life values of Kip1 mRNA
are slightly longer than what would be expected from the
results of Fig. 7. This is likely due to the inherent impreci-
sion associated with the measure of low abundant mes-
sages with short half-lives (Harrold et al., 1991).
The Failure of Ang II to Promote S Phase Entry of 
Aortic SMC Is Not Explained by Autocrine Production 
of TGF-b1
TGF-b1 is the prototype of a family of growth factors that
play important roles in cellular growth, differentiation,
and morphogenesis (Massague, 1990). In particular, TGF-
b1 is a potent growth inhibitor for many cell types, includ-
ing vascular SMC (Owens et al., 1988). Several mecha-
nisms have been proposed to explain how TGF-b1 inhibits
proliferation and induces cell cycle arrest in G1 phase
(Hannon and Beach, 1994; Reynisdottir et al., 1995). The
observation that Ang II can induce hypertrophic or mito-
genic effects in vascular SMC has led to the hypothesis
that Ang II activates both proliferative and antiprolifera-
tive, specifically TGF-b1, signals (Gibbons et al., 1992).
Therefore, we carried out a series of experiments to test
the possibility that autocrine production of TGF-b1 may
be responsible for the failure of Ang II to activate Cdk2
and induce DNA synthesis in aortic SMC. To determine
whether Ang II stimulates the production of active TGF-b1,
we used a highly sensitive bioassay that is based on the
Figure 7. PDGF-BB produces a rapid and transient decrease of
Kip1 mRNA accumulation in aortic SMC. Quiescent aortic SMC
were stimulated with 100 nM Ang II or 50 ng/ml PDGF-BB for
the indicated times. Total cellular RNA was extracted from the
cells and analyzed by Northern hybridization using a 32P-labeled
Kip1 probe (A). The results were normalized by rehybridization
of the blot with a 18S ribosomal RNA oligonucleotide probe (B).
Similar results were obtained in five different experiments.
Figure 8. PDGF-BB reduces transcription of Kip1 gene in aortic
SMC. A, Quiescent aortic SMC were stimulated with 100 nM
Ang II or 50 ng/ml PDGF-BB for 2 h. Nuclei were isolated and
the 32P-labeled nascent transcripts were hybridized to the indi-
cated plasmid DNAs as described in Materials and Methods. The
plasmid DNA inserts used in this experiment were pBluescript-
SK vector (pBS), smooth muscle a-actin (a-actin),  Kip1, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). B, Den-
sitometric analysis of the data shown in A expressed as the ratio
Kip1/GAPDH. Similar results were obtained in two different ex-
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ability of TGF-b to induce G1 arrest in Mv1Lu cells. Fig.
10 A shows that addition of 10 pM TGF-b1 to Mv1Lu cells
is sufficient to inhibit DNA synthesis by 90%. This inhibi-
tory activity of TGF-b1 is reversed by coincubation with
TNA, but not with normal rabbit IgG. However, condi-
tioned medium from Ang II-treated aortic SMC did not
inhibit Mv1Lu cells DNA synthesis, but rather had a sig-
nificant stimulatory effect (Fig. 10 B). We also tested the
effect of TNA on the ability of Ang II to stimulate DNA
synthesis in aortic SMC. Coincubation of Ang II with nor-
mal rabbit IgG or TNA had essentially no effect on the
rate of DNA synthesis (Fig. 10 C). Finally, we examined
the effect of simultaneous exposure of aortic SMC to both
PDGF-BB and Ang II. Simultaneous addition of Ang II or
pretreatment with Ang II (data not shown) did not inter-
Figure 9. Effect of Ang II and PDGF-BB on the stability of Kip1
mRNA. A, DRB method. Quiescent aortic SMC were either left
untreated or stimulated with 100 nM Ang II or 50 ng/ml PDGF-
BB for the indicated times in the presence of 25 mg/ml DRB. To-
tal cellular RNA was extracted from the cells and analyzed by
Northern hybridization using a 32P-labeled Kip1 probe. The hy-
bridization signals were quantified using a PhosphorImager ap-
paratus.  s, Unstimulated cells; d, Ang II-treated cells; m,
PDGF-BB–treated cells. Data points represent the mean of three
separate experiments. B, Pulse-chase method. Quiescent aortic
SMC were pulse-labeled with [3H]uridine for 12 h and chased
with unlabeled uridine and cytidine in the presence or absence of
Ang II or PDGF-BB. The effective chase was started 2 h after ad-
dition of cold nucleosides (zero time point). At different times,
total  3H-labeled RNA was isolated and hybridized to Kip1
cDNA immobilized onto nitrocellulose filters. Data points are
the mean of two separate experiments. For each method, the val-
ues are expressed as percentage of time zero. The solid lines rep-
resent the least-squares fit of the data obtained by linear regres-
sion analysis.
fere with PDGF-BB–induced DNA synthesis (Fig. 10 C)
or p27Kip1 downregulation (Fig. 10 D), consistent with the
idea that Ang II does not stimulate the synthesis of an an-
timitogenic factor. Together, these results demonstrate
that the failure of Ang II to promote S phase entry of aor-
tic SMC is not due to autocrine production of TGF-b1.
Discussion
Unlike cardiac and skeletal muscle cells, which undergo
terminal and irreversible differentiation, vascular SMC
display remarkable cellular plasticity that allows them to
acquire a spectrum of different phenotypes in response to
appropriate stimuli (Owens, 1995). In addition to their
main function of contraction, vascular SMC can increase
their mass through cellular proliferation, cellular hyper-
trophy, and production of extracellular matrix proteins.
Changes in growth rates occur normally during develop-
ment of the vascular system and after vascular injury, but
also under pathological conditions such as hypertension
and atherosclerosis (Schwartz et al., 1986; Owens, 1989;
Ross, 1993). In animal models of hypertension, the in-
crease in vascular mass is associated primarily with SMC
hypertrophy in large arteries and with hyperplasia in small
resistance vessels. SMC proliferation also plays a central
role in the atherosclerotic process. The growth response of
vascular SMC is clearly dependent on the nature of the
growth stimulus. For example, in cultured rat aortic SMC,
agonists like Ang II induce cellular hypertrophy as a result
of increased protein synthesis (Geisterfer et al., 1988; Berk
et al., 1989; Chiu et al., 1991; Grainger et al., 1994; Giasson
and Meloche, 1995), whereas peptide growth factors like
PDGF-BB cause a strong proliferative response (Raines
et al., 1990; Grainger et al., 1994). However, much remains
to be learned about the molecular determinants of vascu-
lar SMC hypertrophic versus hyperplastic growth re-
sponse. Here, we present evidence that p27Kip1 is an im-
portant regulator of the phenotypic response of vascular
SMC. First, we show that treatment with the mitogenic
factor PDGF-BB, but not with the hypertrophic factor
Ang II, leads to a progressive and dramatic decline in the
level of p27Kip1 protein. The failure of Ang II to downregu-
late p27Kip1 results in the increased association of the in-
hibitor with cyclin E–Cdk2 complexes and correlates with
inhibition of threonine 160 phosphorylation of Cdk2.
Since CAK is constitutively active in aortic SMC, the sim-
plest interpretation of our data is that stoichiometric bind-
ing of p27Kip1 to cyclin E–Cdk2 complexes prevents CAK
from phosphorylating and activating Cdk2 in Ang II-
treated cells. In support of this hypothesis, in vitro stud-
ies have shown that p27Kip1 binding to preformed cyclin
E–Cdk2 complexes blocks CAK-mediated threonine 160
phosphorylation of the enzyme (Polyak et al., 1994a;
Aprelikova et al., 1995). Second, we further show that ex-
tracts from Ang II-stimulated cells contain enough CDK
inhibitory activity to reduce by z70% Cdk2-associated
histone H1 kinase activity of PDGF-BB–treated cell ex-
tracts. The stability of this inhibitory activity to heat treat-
ment and its reversal following immunodepletion of
p27Kip1 confirmed that p27Kip1 is the major inhibitory fac-
tor present in these extracts.
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p27Kip1 is regulated by multiple posttranscriptional mecha-
nisms. Our present results add another level of complexity
by demonstrating that the levels of p27Kip1 are also con-
trolled by transcriptional mechanisms in vascular SMC.
Our data support a model where the reduction of p27Kip1
expression observed in response to mitogenic factors oc-
curs by two mechanisms. The first mechanism is a rapid
decrease in the rate of p27Kip1 synthesis that becomes min-
imal by two hours and slowly returns to quiescent value af-
ter  z20 h. This lowered synthesis, combined with the
significant turnover of the protein (see Fig. 6 B), is respon-
sible for the initial decline in p27Kip1 protein levels, which
can be easily detected by eight hours of PDGF-BB stimu-
lation. Detailed kinetic analysis revealed that the reduc-
tion in the rate of p27Kip1 synthesis is tightly paralleled by a
transient downregulation of Kip1 mRNA accumulation.
Importantly, these changes in Kip1 mRNA levels coin-
cide with a marked decrease in the rate of Kip1 gene tran-
scription, suggesting that transcriptional control is an im-
portant factor in regulating the synthesis of p27Kip1. While
other studies have reported changes in the levels of Kip1
mRNA in response to extracellular factors (Kwon et al.,
1996; Liu et al., 1996), our findings provide the first dem-
onstration that p27Kip1 expression is regulated at the level
of gene transcription. We also show that both PDGF-BB
and Ang II significantly decrease the stability of Kip1
mRNA. The almost complete inhibition of Kip1 gene tran-
scription, coupled with the increased turnover of the
mRNA, explains the marked downregulation of Kip1
mRNA expression observed in PDGF-BB–treated cells.
Further studies are clearly necessary to identify the cis-act-
ing elements that target Kip1 mRNA for degradation and
the corresponding RNA-binding proteins. In addition to
transcription, other levels of control may also be involved
in the regulation of p27Kip1 synthesis. Figs. 6 C and 7 show
that the rate of p27Kip1 synthesis is still repressed in PDGF-
BB–treated cells after 12–20 h when Kip1 mRNA has re-
turned to control levels. One possibility is that Kip1
mRNA is not being used efficiently by the translation ma-
chinery during G1 progression because of the binding of
mRNA masking proteins (Spirin, 1996). In support of this
idea, it was found that the accumulation of p27Kip1 protein
observed during growth arrest of HL-60 cells is due to an
increase in the amount of Kip1 mRNA in polyribosomes
(Millard et al., 1997). The second mechanism of p27Kip1
elimination is an increase in the degradation rate of the
protein, which is mostly evident by eight hours of mito-
genic stimulation. By contrast, treatment of vascular SMC
Figure 10. Ang II does not stimulate autocrine production of
TGF-b1 in aortic SMC. A, TGF-b1 bioassay. Mv1Lu cells were
treated for 24 h with 10 pM TGF-b1 in the absence or presence of
10–15  mg/ml of TNA or normal rabbit IgG (NRS). B, Condi-
tioned medium from Ang II-stimulated aortic SMC (1:5 dilution)
was added alone or in combination with 10 mg/ml TNA to Mv1Lu
cells. C, Quiescent aortic SMC were stimulated for 24 h with 100
nM Ang II in the absence or presence of 10 mg/ml TNA or NRS.
In the same experiment, the cells were stimulated with 50 ng/ml
PDGF-BB alone or in the presence of 100 nM Ang II. The rate of
DNA synthesis was measured by [3H]thymidine incorporation
during the last 4–6 h of stimulation. Each value represents the
mean 6 SEM of triplicate determinations. The data presented
are representative of at least two different experiments with simi-
lar results. D, Expression of p27Kip1 protein. Quiescent aortic
SMC were stimulated with 100 nM Ang II or 50 ng/ml PDGF-BB
or with both agonists for a 20-h period. The expression of p27Kip1
protein was analyzed by immunoblotting.The Journal of Cell Biology, Volume 148, 2000 554
with hypertrophic factors like Ang II less effectively re-
presses p27Kip1 synthesis and does not affect the rate of
degradation of the protein.
The signaling pathways that are involved in the regula-
tion of Kip1 gene transcription remain to be identified. As
mentioned earlier, PDGF-BB and Ang II activate several
common signaling events in aortic SMC. However, signifi-
cant differences are noted in the time course of these
events. For example, PDGF-BB induces a sustained acti-
vation of the MAP kinases ERK1/ERK2, whereas Ang II
has a very transient effect (Plevin et al., 1996; and data not
shown). PDGF-BB and Ang II are also known to have dif-
ferent effects on the source and duration of the increase
in cytosolic-free calcium in vascular SMC (Roe et al.,
1989; Brinson et al., 1998). In addition, mitogenic and
hypertrophic factors are likely to trigger unique signaling
events. Studies in pulmonary arterial SMC have shown
that PDGF-BB exclusively stimulates an increase in phos-
phatidylinositol 3,4,5-trisphosphate (Button et al., 1994),
whereas only thrombin, which behaves as a hypertrophic
factor, induces fosB mRNA levels (Rothman et al., 1994).
However, these observations may not be generalized to
other SMC types, since both PDGF-BB and Ang II acti-
vate PI3-kinase and induce fosB mRNA in rat aortic SMC
(Saward and Zahradka, 1997; and data not shown). Char-
acterization of the 59 flanking region of the mouse Kip1
gene showed that a region between 2326 to 2615 is suffi-
cient to confer maximal basal promoter activity (Kwon et
al., 1996; Zhang and Lin, 1997). Constructs extending be-
yond 2615 displayed lower basal promoter activity, sug-
gesting that a negative regulatory element may be con-
tained in the region between 2615 and 21,609 (Kwon et al.,
1996). However, these studies did not examine the serum
or growth factor responsiveness of the various KipI gene
promoter constructs. Work is in progress in our laboratory
to identify specific regions within the promoter of the rat
KipI gene which mediate PDGF-BB dependent transcrip-
tional repression.
The turnover of p27Kip1 is also subject to regulation by
mitogenic factors in vascular SMC. Given the recent dem-
onstration that cyclin E–Cdk2 directly phosphorylates
p27Kip1 on threonine 187 and promotes its elimination
from the cell (Sheaff et al., 1997; Vlach et al., 1997), it is
tempting to speculate that the different rates of p27Kip1
turnover observed in PDGF-BB or Ang II-treated cells
are a reflection of their differential ability to activate Cdk2.
In agreement of this idea, we found that in vivo phosphor-
ylation of p27Kip1 increases after 8–12 h in cells exposed to
PDGF-BB, but not in response to Ang II (data not
shown). However, phosphorylation by Cdk2 is unlikely to
be the sole mechanism that regulates the proteolysis of
p27Kip1. Indeed, significant degradation of the inhibitor is
observed during the first hours of growth factor stimula-
tion, in the absence of detectable histone H1 kinase activ-
ity (Pagano et al., 1995; Agrawal et al., 1996; this study).
We also found that in vascular SMC and other cell types,
p27Kip1 is significantly phosphorylated in G0 and early G1
phase (data not shown). These observations suggest that
other protein kinases and/or mechanisms signal p27Kip1 for
degradation. In this respect, it was reported that Ras sig-
naling is required for downregulation of p27Kip1 in rodent
fibroblasts (Aktas et al., 1997; Takuwa and Takuwa, 1997;
Kawada et al., 1997) and that RhoA is a necessary media-
tor of p27Kip1 degradation (Weber et al., 1997).
It has been postulated that the failure of Ang II to stim-
ulate vascular SMC hyperplasia is due to autocrine pro-
duction of the antimitogenic cytokine TGF-b1 by these
cells (Gibbons et al., 1992; Koibuchi et al., 1993). How-
ever, our results do not support this model. First, active
TGF-b1 was not detected in the supernatant of Ang II-
treated aortic SMC. Second, the use of a neutralizing anti-
body against TGF-b1 in combination with Ang II did not
potentiate DNA synthesis in these cells. Third, pretreat-
ment of aortic SMC for four hours with Ang II before
PDGF-BB stimulation (data not shown) or simultaneous
addition of both factors did not affect the mitogenic re-
sponse to PDGF-BB.
Previous in vivo studies have demonstrated that Cdk2
function is required for intimal SMC accumulation after
angioplasty in the rat carotid artery (Abe et al., 1994; Mor-
ishita et al., 1994). In addition, Cdk2 expression is tempo-
rally correlated with vascular SMC proliferation after an-
gioplasty (Wei et al., 1997). More recently, it was reported
that p27Kip1 is markedly upregulated after balloon angio-
plasty in the rat carotid artery and that high levels of
p27Kip1 expression correlates with downregulation of Cdk2
kinase activity (Chen et al. 1997). Ectopic overexpression
of p27Kip1 in injured arteries attenuated neointimal lesion
formation. A recent study also presented evidence that po-
lymerized collagen inhibits aortic SMC proliferation in
vitro through a2 integrin-mediated upregulation of p27Kip1
(Koyama et al., 1996). Thus, the results presented here, to-
gether with these findings, clearly identify p27Kip1 as an im-
portant regulator of vascular SMC growth response.
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